Shares of Pharma Aids, a pioneer in glass ampoule manufacturing for the pharmaceutical industry in Bangladesh, plunged by 9.19% to Tk514.60 on the Dhaka Stock Exchange (DSE) yesterday, despite a 4.42% growth in profit and a higher cash dividend recommendation for the 2024-25 fiscal year.

According to a disclosure published on the stock exchanges yesterday, the pharmaceuticals and chemicals sector-listed firm recommended a 30% cash dividend for its shareholders, up from 25% in the previous fiscal year.

According to the DSE data, the adjusted opening price of Pharma Aids shares was Tk566.70 each today (9 November). During the day, the shares traded between Tk510.10 and Tk561, before closing at Tk514.60 each.

The firm, listed in 1987, reported a profit of Tk6.38 crore with an earnings per share (EPS) of Tk20.45 for FY24, which was Tk6.11 crore and an EPS of Tk19.61 in FY24, its data showed. 

The company said the 30% cash dividend is recommended keeping in mind the necessity of funds for land acquisition and the upcoming BMRE (Balancing, Modernisation, Rehabilitation, and Expansion) project.

Pharma Aids has scheduled its annual general meeting (AGM) for 24 December through digital platform. The company has set 7 December as the record date to identify eligible shareholders.

The net operating cash flow per share for the year ended in June 2025 increased to Tk12.74, and net asset value per share to Tk138.58, which was Tk7.30 and Tk109.89 respectively in the same period of the previous fiscal year, it data showed. 

Of the total shares of 31.20 lakh, sponsor-directors held 23.58%, institutional investors 19.09%, and the general public held 57.33% shares of the company as of 31 October 2025. 

 

Pharma Aids Ltd / Dhaka Stock Exchange (DSE)